GI Stool Testing Market Size & Share, Growth, Forecast Report 2034

GI Stool Testing Industry Prospective:

The global GI stool testing market size was worth around USD 1,025.26 million in 2024 and is predicted to grow to around USD 2,404.99 million by 2034, with a compound annual growth rate (CAGR) of roughly 8.90% between 2025 and 2034.

Request Free Sample

GI Stool Testing Market: Overview

Gastrointestinal (GI) stool testing is a medical diagnostic procedure used to detect viruses, bacteria, or parasites in a patient's GI system. GI stool testing is also known as a fecal test or stool culture. Additionally, healthcare providers may also recommend stool tests to look for other signs in the body that may suggest a disease or a medical condition. According to the Cleveland Clinic, GI stool tests are prescribed in case of certain types of cancer, infections, and other GI issues.

For instance, the presence of blood or mucus in fecal matter, cramping & excessive stomach pain, diarrhea, fever, and vomiting for days are some of the prominent symptoms encouraging medical professionals to prescribe stool tests. The industry is currently led by three types of GI stool testing. These include the fecal immunochemical test (FIT), the Deoxyribonucleic Acid (DNA) test, the Fecal occult blood test (FOBT), and a test for infection. The growing prevalence of GI-related medical conditions is fueling the market revenue. Additionally, growing access to diagnostic centers and healthcare facilities may further propel the industry’s growth rate in the future. However, advancements in novel testing methods as an alternative to stool testing may impede market expansion in the coming years.

Key Insights:

• As per the analysis shared by our research analyst, the global GI stool testing market is estimated to grow annually at a CAGR of around 8.90% over the forecast period (2025-2034)
• In terms of revenue, the global GI stool testing market size was valued at around USD 1,025.26 million in 2024 and is projected to reach USD 2,404.99 million by 2034.
• The GI stool testing market is projected to grow at a significant rate due to the growing prevalence of GI-related medical conditions.
• Based on the product type, the consumables segment is growing at a high rate and will continue to dominate the global market as per industry projections.
• Based on the indication, the cancer segment is anticipated to command the largest market share.
• Based on region, North America is projected to dominate the global market during the forecast period.

GI Stool Testing Market: Growth Drivers

Growing prevalence of GI-related medical conditions to promote market expansion

The global GI stool testing market is expected to be driven by the rising prevalence of gastrointestinal medical disorders. Stool tests are generally recommended for conditions such as anemia, anal fissures, colon polyps, colitis, colon cancer, GI bleeding, exocrine pancreatic insufficiency, infections, hemorrhoids, steatorrhea, and stomach ulcers. These conditions can be triggered by a wide range of causes. For instance, colon cancer, according to healthcare researchers, is caused by age, inherited gene mutation, smoking, lack of physical activity, and inflammatory bowel disease.

On the other hand, bacterial or parasitic infections are related to the consumption of contaminated water or food, as well as contact with an infected object or person. Infections caused by bacteria  Campylobacter, Salmonella, E. coli, and Shigella are some of the most commonly occurring conditions. Changes in lifestyle, including a lack of sufficient physical activity, poor eating habits, and excessive consumption of processed or junk food, can be leading reasons for commonly occurring GI conditions, resulting in greater demand for stool testing for diagnostic purposes.

Increasing access to healthcare facilities and diagnostic clinics to further promote the market growth rate

In recent times, global economies have witnessed increased health expenditure driven by surging demand for quality and inclusive healthcare. The rising number of diagnostic centers worldwide has helped deliver more revenue in terms of fecal testing. For instance, as of 2025, Egypt is witnessing the construction of the New Capital Hospital City worth USD 800 million.

The facility will be equipped with more than 4200 beds and will also encompass a new University of Medical Sciences. Furthermore, government support for domestic healthcare and diagnostic infrastructure, in the form of affordable medical insurance policies and subsidies for low-income families, may further aid the expansion of the global GI stool testing market.

GI Stool Testing Market: Restraints

Lack of patient compliance and cost of advanced tests will limit market expansion in the long term

The global GI stool testing industry is expected to be restricted due to a lack of patient compliance. Presently, stool collecting for the testing process involves manual management of fecal matter. Patients may feel discomfort in collecting the sample. Additionally, the high cost of advanced tests may further affect the market revenue in the long run. For instance, tests for stool culture to detect infections may cost between USD 100 and USD 300.

GI Stool Testing Market: Opportunities

Improvements in diagnostic technologies and increased regulatory approvals to generate growth opportunities

The global GI stool testing market is expected to generate growth opportunities due to the surging improvements in diagnostic technologies. In addition, increasing the number of regulatory approvals for novel stool tests may further escalate market revenue, according to research. For instance, in March 2025, Exact Sciences Corp, a leading provider of cancer screening and diagnostic tests, launched Cologuard Plus™.

According to official reports, it is the latest and most accurate noninvasive colorectal cancer screening (CRC) test. Cologuard Plus received US Food & Drug Administration (FDA) approval for average-risk patients 45+. It accurately detects 95% of colorectal cancers with 94% specificity. The technology detects specific DNA markers and blood in stool.

In May 2024, the agency approved ColoSense by Geneoscopy, Inc. As per official reports, ColoSense is a non-invasive colorectal cancer screening test, with a 93% sensitivity rate. In a recent event, The Lancet Oncology reported that researchers in the Netherlands developed a new screening test for bowel cancer. The test is considered more accurate in detecting larger polyps than the available stool test.

Request Free Sample

GI Stool Testing Market: Challenges

Ongoing advancements in the development of alternatives to stool tests may challenge market expansion

The global GI stool testing industry is expected to be challenged by the ongoing advancements in technologies alternative to stool testing. For instance, in November 2024, MicrobioTix, an Indian medical technology company, launched India’s first finger-prick-based gut microbiome test, eliminating the need for stool testing. Such advancements are likely to impact market revenue during the forecast period.

GI Stool Testing Market: Report Scope

GI Stool Testing Market: Segmentation

The global GI stool testing market is segmented based on product type, test type, indication, end-user, and region.

Based on the product type, the global market segments are analyzers and consumables. During the forecast period, the industry was dominated by the consumables segment. The growing use of reagents, test kits, and collection devices is fueling segmental revenue. It dominated more than 60% of the total revenue in 2024, and the same trend can be expected in the future.

Based on test type, the global GI stool testing is divided into fecal biomarkers test, ova & parasite test, occult blood test, and others.

Based on the indication, the global market divisions are cancer, gastroesophageal reflux disease, inflammatory bowel disease, and others. In 2024, the highest revenue-generating segment was cancer due to the growing prevalence of colorectal cancer worldwide. As per the World Health Organization (WHO), more than 1.9 million cases of colorectal cancer were reported worldwide in 2024.

Based on end-users, the global market divisions are research centers & organizations, diagnostic centers & laboratories, hospitals, and others.

GI Stool Testing Market: Regional Analysis

North America to dominate the market during the projection period

The global GI stool testing market is expected to be led by North America during the forecast period. The US is expected to lead the regional industry. One of the primary reasons for increased regional revenue is the widespread awareness of the benefits of preventive care among the general population.

Furthermore, the growing prevalence of colon cancer among the regional population will fuel higher revenue in North America. In recent times, the US has seen an increase in regulatory approvals for testing technologies that use stool samples to diagnose a wide range of gastrointestinal diseases.

Europe is another growing market expected to emerge as the second-highest revenue generator. The existence of a growing geriatric population has led to an increased number of patients with GI conditions. Moreover, the inclusive healthcare infrastructure of major European countries, such as Spain, Germany, and others, has promoted increased regional revenue.

In July 2024, Mainz Biomed N.V., a German molecular genetics diagnostic company, announced enhancements to its ColoAlert offering. It is an at-home detection test for colorectal cancer using breakthrough technology for DNA analysis in case of the presence of colon cancer cells.

GI Stool Testing Market: Competitive Analysis

The global GI stool testing market is led by players like:

• GI-MAP (Diagnostic Solutions Laboratory)
• Genova Diagnostics
• Quest Diagnostics
• Eurofins Scientific
• Thorne HealthTech
• Atlas Biomed
• Onegevity Health
• BioReference Laboratories
• Doctor's Data Inc.
• DayTwo
• Labcorp
• uBiome
• Everlywell
• Invivo Healthcare
• Viome

The global GI stool testing market is segmented as follows:

By Product Type

• Analyzers
• Consumables

By Test Type

• Fecal Biomarkers Test
• Ova & Parasite Test
• Occult Blood Test
• Others

By Indication

• Cancer
• Gastroesophageal Reflux Disease
• Inflammatory Bowel Disease
• Others

By End-User

• Research Centers & Organizations
• Diagnostic Centers & Laboratories
• Hospitals
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa